Vishal Peddagangireddy
Overview
Explore the profile of Vishal Peddagangireddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tompkins A, Gray Z, Dadey R, Zenkin S, Batavani N, Newman S, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39939139
Variability in treatment response may be attributable to organ-level heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive biomarkers of clinical outcome. Organ-specific radiomic comparison across immunotherapies...
2.
Zandberg D, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, et al.
Head Neck
. 2024 Jul;
47(1):129-138.
PMID: 39080968
Background: We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti-PD-1 mAb (IO) in R/M HNSCC. Methods: Radiomic feature extraction was performed on pre-treatment...
3.
Tompkins A, Gray Z, Dadey R, Zenkin S, Batavani N, Newman S, et al.
medRxiv
. 2024 May;
PMID: 38712112
Background: Variability in treatment response may be attributable to organ-level heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive biomarkers of clinical outcome. Organ-specific radiomic comparison across...
4.
de Miguel-Perez D, Ak M, Mamindla P, Russo A, Zenkin S, Ak N, et al.
J Exp Clin Cancer Res
. 2024 Mar;
43(1):81.
PMID: 38486328
Background: Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the...
5.
Alan N, Zenkin S, Lavadi R, Legarreta A, Hudson J, Fields D, et al.
World Neurosurg
. 2024 Jan;
184():e137-e143.
PMID: 38253177
Background: Preoperative symptom severity in cervical spondylotic myelopathy (CSM) can be variable. Radiomic signatures could provide an imaging biomarker for symptom severity in CSM. This study utilizes radiomic signatures of...
6.
de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, et al.
J Exp Clin Cancer Res
. 2022 Jun;
41(1):186.
PMID: 35650597
Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive...
7.
Foster A, Nigam S, Tatum D, Raphael I, Xu J, Kumar R, et al.
EBioMedicine
. 2021 Sep;
71:103571.
PMID: 34530385
Background: Malignant gliomas are deadly tumours with few therapeutic options. Although immunotherapy may be a promising therapeutic strategy for treating gliomas, a significant barrier is the CD11b tumour-associated myeloid cells...